4559 Zeria Pharmaceutical
- 2171
- +16+0.74%
Zeria Pharmaceutical News
Change Report (Stock Certificates Eligible for Special Provisions, etc.)
Zeria Pharmaceutical: Extraordinary Report
Zeria Pharmaceutical: Report on Corporate Governance June 27, 2024.
Zeria Pharmaceutical: Confirmation letter
Zeria Pharmaceutical: Internal Control Report - 70th Term (2023/04/01 - 2024/03/31)
Zeria Pharmaceutical: Securities Report - 70th period (April 1, 2023 - March 31, 2024)
Zeria Pharmaceutical: Announcements of individual stocks: Development and sales contract for functional dyspepsia treatment using acotiamide hydrochloride hydrate in European, USA, and Canada regions.
Zeria Pharmaceutical: Announcements of individual stocks regarding the absorption merger (simple merger, abbreviated merger) of a wholly-owned subsidiary.
Zeria Pharmaceutical: Announcements of individual stocks regarding compliance with listing maintenance criteria.
Zeria Pharmaceutical: [Delayed] Consolidated Earnings for the Fiscal Year Ended 2024/3/31 [Japanese Accounting Standards]
Zeria Pharmaceutical: Notice of the 2024 Convocation Annual General Meeting
Zeria Pharmaceutical: 2024 Annual General Meeting of Shareholders materials (matters not described in the issuance document)
Zeria Pharmaceutical: 2024 Annual General Shareholders' Meeting Convocation Notice and Shareholders' Meeting Materials
Zeria Pharmaceutical: Change Report
Zeria Pharmaceutical: 2024 financial results overview
Zeria Pharmaceutical: Notice regarding executive personnel affairs
Zeria Pharmaceutical: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Zelia Pharmaceutical: Change Report
Zeria Pharmaceutical: Notice Concerning Organizational Changes and Executive Personnel
Zeria Pharmaceutical: [Delayed]Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2024[Japanese GAAP]
Analysis
Price Target
No Data
